Výsledky vyhledávání - "Tobias, Furlan"

Akademický článek

The oxidoreductase p66Shc acts as tumor suppressor in BRAFV600E‐transformed cells

Autor: Tobias Furlan, Sana Khalid, Anh‐Vu Nguyen, Julia Günther, Jakob Troppmair

Publikováno v: Molecular Oncology, Vol 12, Iss 6, Pp 869-882 (2018)

Metabolic reprogramming, as exemplified by the shift from oxidative phosphorylation to glycolysis, is a common feature of transformed cells. In many tumors, altered metabolism is also reflected in increased reactive oxygen species (ROS) levels, which

Externí odkaz: https://doaj.org/article/1cead740927a4c9e9b5a4e9b1a241f7c

Zobrazit plný text záznamu

Supplementary Table S2 from Increased Expression of miR-23a Mediates a Loss of Expression in the RAF Kinase Inhibitor Protein RKIP

Autor: Armin Zebisch, Heinz Sill, Jakob Troppmair, Albert Wölfler, Franz Quehenberger, Mojca Jongen-Lavrencic, Katarzyna Nowek, Marcel Scheideler, Martin Pichler, Rotraud Wieser, Erika Nussbaumer, Tobias Furlan, Till Seime, Veronica Caraffini, Maja Kim Kuepper, Olivia Geiger, Stefan Hatzl

Datasets downloaded from TCGA.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a89f91f7c4217c4474987ce6b51bce3
https://doi.org/10.1158/0008-5472.22411184

Zobrazit plný text záznamu

Supplementary Figure Legends from Increased Expression of miR-23a Mediates a Loss of Expression in the RAF Kinase Inhibitor Protein RKIP

Supplementary Figure Legends

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::106bf3c9f0e562924aa5e10a58434d32
https://doi.org/10.1158/0008-5472.22411208

Zobrazit plný text záznamu

Supplementary Figure S4 from Increased Expression of miR-23a Mediates a Loss of Expression in the RAF Kinase Inhibitor Protein RKIP

RKIP knockdown in U937 does not affect NF-κB.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28dfbf4c715c252b01ed1537dd46b666
https://doi.org/10.1158/0008-5472.22411196

Zobrazit plný text záznamu

Data from Increased Expression of miR-23a Mediates a Loss of Expression in the RAF Kinase Inhibitor Protein RKIP

RAF kinase inhibitor protein (RKIP) is a seminal regulator of intracellular signaling and exhibits both antimetastatic and antitumorigenic properties. Decreased expression of RKIP has been described in several human malignancies, including acute myel

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2897a5aef721149133faacfd76539087
https://doi.org/10.1158/0008-5472.c.6508172

Zobrazit plný text záznamu

MYC-Mediated Ribosomal Gene Expression Sensitizes Enzalutamide-resistant Prostate Cancer Cells to EP300/CREBBP Inhibitors

Autor: Martin Puhr, Frédéric R. Santer, Zlatko Trajanoski, Martina Gruber, Natalie Sampson, Walther Parson, Zoran Culig, Tobias Furlan, Florian Handle, Alexander Kirchmair

Publikováno v: The American Journal of Pathology. 191:1094-1107

Patients with advanced prostate cancer are frequently treated with the antiandrogen enzalutamide. However, resistance eventually develops in virtually all patients, and various mechanisms have been associated with this process. The histone acetyltran

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f69013d40c0fde9b967526d17adef7de
https://doi.org/10.1016/j.ajpath.2021.02.017

Zobrazit plný text záznamu

HUS1 as a Potential Therapeutic Target in Urothelial Cancer

Autor: Andrea Katharina Lindner, Tobias Furlan, Jacob J. Orme, Gennadi Tulchiner, Nina Staudacher, David D’Andrea, Zoran Culig, Renate Pichler

Publikováno v: Journal of clinical medicine. 11(8)

Platinum-based chemotherapy is the standard of care with concern to first-line systemic therapy for metastatic disease in urothelial cancer (UC). Resistance to chemotherapy despite an initial response is linked with the ability to remove platinum-bas

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf7bbfe4b35831c6466f2bcbd97912b3
https://pubmed.ncbi.nlm.nih.gov/35456300

Zobrazit plný text záznamu

Plný text ve formátu HTML

Abstract 2686: Is ARV7 a regulator of prostate cancer stemness and plasticity

Autor: Tobias Furlan, Florian Handle, Marcus V. Cronauer, Frédéric R. Santer

Publikováno v: Cancer Research. 82:2686-2686

Therapy options for advanced and castration-resistant prostate cancer (CRPC) include the use of drugs targeting directly/indirectly the ligand binding domain (LBD) of androgen receptor (AR) such as enzalutamide (Enza) and abiraterone acetate. However

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ff1ba78ddc2b614221172f70896aae18
https://doi.org/10.1158/1538-7445.am2022-2686

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání